FTY720 Attenuates Infection-Induced Enhancement of Aβ Accumulation in APP/PS1 Mice by Modulating Astrocytic

Róisín M McManus1,2, Orla M Finucane1, Mieszko M Wilk2

  • 1Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Ireland.

Insights

FTY720 treatment reduced infection-induced brain damage and amyloid-beta plaque accumulation in a mouse model of Alzheimer's disease (AD). This neuroprotective effect is linked to enhanced astrocyte phagocytosis of amyloid-beta.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Infections exacerbate Alzheimer's disease (AD) pathology, increasing neuroinflammation and amyloid-beta (Aβ) accumulation.
  • Susceptibility to infection increases with age and in AD patients, worsening disease progression.
  • FTY720, an S1P receptor modulator used for multiple sclerosis, has immunosuppressive properties.

Purpose of the Study:

  • To investigate if FTY720 can mitigate the detrimental effects of infection in a mouse model of AD.
  • To determine FTY720's impact on infection-induced neuroinflammation, blood-brain barrier (BBB) permeability, and Aβ pathology.

Main Methods:

  • Transgenic amyloid precursor protein/presenilin 1 (APP/PS1) mice were infected with Bordetella pertussis.
  • Mice received oral FTY720 or vehicle treatment starting three days before infection.
  • Evaluated astrocytic activation, BBB permeability, and Aβ plaque and soluble Aβ levels.

Main Results:

  • Infection increased astrocytic activation and BBB permeability, which were attenuated by FTY720 treatment.
  • B. pertussis infection elevated Aβ plaques and soluble Aβ; FTY720 treatment reduced these infection-related increases.
  • FTY720's protective effects appear to stem from increased Aβ phagocytosis by astrocytes.

Conclusions:

  • FTY720 effectively reduces infection-induced neuropathology and Aβ burden in an AD mouse model.
  • The drug's mechanism involves enhancing astrocyte-mediated Aβ clearance.
  • FTY720 shows potential for managing acute inflammatory challenges in AD, but not genotype-related changes without infection.

Related Concept Videos